Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
69 hedge funds and large institutions have $65.2M invested in Viracta Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 12 closing their positions.
1% more funds holding
Funds holding: 68 → 69 (+1)
8% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 12
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
27% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 22
48% less capital invested
Capital invested by funds: $125M → $65.2M (-$59.4M)
58% less call options, than puts
Call options by funds: $143K | Put options by funds: $341K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.91M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$1.84M |
| 3 |
BlackRock
New York
|
+$1.51M |
| 4 |
Two Sigma Investments
New York
|
+$850K |
| 5 |
Renaissance Technologies
New York
|
+$617K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASP
Adams Street Partners
Chicago,
Illinois
|
-$5.85M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.27M |
| 3 |
JP Morgan Chase
New York
|
-$2.99M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.07M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
UBS Group
Zurich,
Switzerland
| – | -$4.6K | -862 | -99% |
|
|
RE
77
RBC Europe
London,
United Kingdom
| – | -$6.01K | -749 | Closed |
|
78
Fidelity Investments
Boston,
Massachusetts
| – | -$16 | -3 | -21% |
|
VIRX Hedge Fund Activity: Q4 2021 in Review
69 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q4 2021, worth a combined $65.2M — down 48% from $125M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new VIRX positions and 12 closed out — a net gain of 1 holder — while 16 added to existing stakes and 22 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $2.91M. The largest seller was Adams Street Partners, exiting entirely with an estimated $5.85M sold.
- 69 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q4 2021, up from 68 in Q3 2021.
- Funds reported $65.2M of Viracta Therapeutics, Inc. Common Stock stock for Q4 2021, down 48% quarter-over-quarter.
- 13 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q4 2021 and 12 closed out, a net change of +1 holder.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q4 2021 was Morgan Stanley, an estimated $2.91M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q4 2021 was Adams Street Partners, an estimated $5.85M sold.
Based on aggregated 13F filings for Q4 2021.